Concomitant Use of Levothyroxine and Proton Pump Inhibitors in Patients with Primary Hypothyroidism: a Systematic Review

Overview

Journal J Gen Intern Med

Publisher Springer

Specialty General Medicine

Date 2021 Jan 20

PMID 33469743

Citations 6

Authors

Yuli Guzman-Prado

Roberto Vita

Ondrej Samson

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to assess the effect of concomitant use of levothyroxine (LT4) and proton pump inhibitors (PPIs) on thyroid-stimulating hormone (TSH) levels in patients with primary hypothyroidism.

Methods: A systematic review of interventional and observational studies that compared the TSH levels before and after concomitant use of LT4 and PPI was performed. Articles published in English up to September 1, 2019, were included. PubMed, EMBASE, and Cochrane Library databases. Gray literature was also searched in repositories, websites OpenGrey and Google Scholar, and abstracts of major international congresses. Study quality was assessed with the Newcastle-Ottawa quality assessment scale for observational studies and the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool was used.

Results: Five thousand twelve discrete articles were identified. Following assessment and application of eligibility criteria, seven studies were included. There was a considerable heterogeneity among the included studies in design, sample size, inclusion and exclusion criteria, treatment regimen, and baseline demographics. Each of the included studies showed an increase in TSH levels following LT4 and PPI consumption, and in the majority of these, the increase was statistically significant.

Discussion: The concomitant use of LT4 and PPI showed a significant increase in TSH concentration. However, given the small number of studies, further research is needed to clarify the interfering role of PPI on LT4 intestinal absorption.

Prospero Registration Number: CRD42020047084.

Citing Articles

Thyroid hormone replacement therapy in dialysis/renal insufficiency patients.

Zhao X, Liu F, Yuan S, Wang F, Li C, Guo C Front Endocrinol (Lausanne). 2025; 16:1540802.

PMID: 40078580 PMC: 11897748. DOI: 10.3389/fendo.2025.1540802.

Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic Review.

Liu H, Lu M, Hu J, Fu G, Feng Q, Sun S Ther Clin Risk Manag. 2023; 19:503-523.

PMID: 37384019 PMC: 10295503. DOI: 10.2147/TCRM.S414460.

The interplay between vitamin C and thyroid.

Far B, Behnoush A, Ghondaghsaz E, Habibi M, Khalaji A Endocrinol Diabetes Metab. 2023; 6(4):e432.

PMID: 37246589 PMC: 10335618. DOI: 10.1002/edm2.432.

Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption.

Gatta E, Bambini F, Buoso C, Gava M, Maltese V, Anelli V Front Endocrinol (Lausanne). 2022; 13:1080108.

PMID: 36561558 PMC: 9764388. DOI: 10.3389/fendo.2022.1080108.

Pharmacokinetic Interaction of Anaprazole, Amoxicillin and Clarithromycin after Single-Dose Simultaneous Administration and the Effect of Adding Bismuth on Their Pharmacokinetics in Healthy Male Chinese Subjects.

Ding S, Xie L, Wang L, Zhou C, Zhou S, Chen J Eur J Drug Metab Pharmacokinet. 2022; 48(2):121-132.

PMID: 36520316 DOI: 10.1007/s13318-022-00810-8.

References

Hennessey J . The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2016; 55(1):6-18. DOI: 10.1007/s12020-016-1199-8. View

Cappola A, Arnold A, Wulczyn K, Carlson M, Robbins J, Psaty B . Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab. 2014; 100(3):1088-96. PMC: 4333030. DOI: 10.1210/jc.2014-3586. View

Jonklaas J, Bianco A, Bauer A, Burman K, Cappola A, Celi F . Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 24(12):1670-751. PMC: 4267409. DOI: 10.1089/thy.2014.0028. View

Liwanpo L, Hershman J . Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009; 23(6):781-92. DOI: 10.1016/j.beem.2009.06.006. View

Benvenga S, Bartolone L, Pappalardo M, Russo A, Lapa D, Giorgianni G . Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. 2008; 18(3):293-301. DOI: 10.1089/thy.2007.0222. View

Benvenga S, Di Bari F, Vita R . Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017; 56(1):138-145. DOI: 10.1007/s12020-017-1244-2. View

Virili C, Bassotti G, Santaguida M, Iuorio R, Del Duca S, Mercuri V . Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J Clin Endocrinol Metab. 2012; 97(3):E419-22. DOI: 10.1210/jc.2011-1851. View

Benvenga S, Vita R, Di Bari F, Fallahi P, Antonelli A . Do Not Forget Nephrotic Syndrome as a Cause of Increased Requirement of Levothyroxine Replacement Therapy. Eur Thyroid J. 2015; 4(2):138-42. PMC: 4521056. DOI: 10.1159/000381310. View

Groener J, Lehnhoff D, Piel D, Nawroth P, Schanz J, Rudofsky G . Subcutaneous application of levothyroxine as successful treatment option in a patient with malabsorption. Am J Case Rep. 2013; 14:48-51. PMC: 3614336. DOI: 10.12659/AJCR.883788. View

10.

Benvenga S . When thyroid hormone replacement is ineffective?. Curr Opin Endocrinol Diabetes Obes. 2013; 20(5):467-77. DOI: 10.1097/MED.0000000000000003. View

11.

Walker J, Shillo P, Ibbotson V, Vincent A, Karavitaki N, Weetman A . A thyroxine absorption test followed by weekly thyroxine administration: a method to assess non-adherence to treatment. Eur J Endocrinol. 2013; 168(6):913-7. DOI: 10.1530/EJE-12-1035. View

12.

Centanni M . Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine. 2012; 43(1):8-9. DOI: 10.1007/s12020-012-9814-9. View

13.

Skelin M, Lucijanic T, Amidzic Klaric D, Resic A, Bakula M, Liberati-cizmek A . Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. Clin Ther. 2017; 39(2):378-403. DOI: 10.1016/j.clinthera.2017.01.005. View

14.

Daher R, Yazbeck T, Jaoude J, Abboud B . Consequences of dysthyroidism on the digestive tract and viscera. World J Gastroenterol. 2009; 15(23):2834-8. PMC: 2699000. DOI: 10.3748/wjg.15.2834. View

15.

Ebert E . The thyroid and the gut. J Clin Gastroenterol. 2010; 44(6):402-6. DOI: 10.1097/MCG.0b013e3181d6bc3e. View

16.

Shin J, Kim N . Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013; 19(1):25-35. PMC: 3548122. DOI: 10.5056/jnm.2013.19.1.25. View

17.

Badillo R, Francis D . Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014; 5(3):105-12. PMC: 4133436. DOI: 10.4292/wjgpt.v5.i3.105. View

18.

Yang J, Kang H, Lee S, Kim J, Sung I, Park H . Recurrence of gastroesophageal reflux disease correlated with a short dinner-to-bedtime interval. J Gastroenterol Hepatol. 2013; 29(4):730-5. DOI: 10.1111/jgh.12455. View

19.

Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G . Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006; 354(17):1787-95. DOI: 10.1056/NEJMoa043903. View

20.

Sachmechi I, Reich D, Aninyei M, Wibowo F, Gupta G, Kim P . Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007; 13(4):345-9. DOI: 10.4158/EP.13.4.345. View